, Volume 26, Issue 6, pp 413–424 | Cite as


In Adult Kidney Transplant Recipients
  • Karly P. Garnock-Jones
Adis Drug Profile


Belatacept is a second-generation cytotoxic T-lymphocyte-associated antigen-4-Ig fusion protein, which down-regulates T-cell response, and is used in the prophylaxis of organ rejection in adults receiving a kidney transplant. This article reviews the pharmacologic properties of belatacept and its clinical efficacy and tolerability in kidney transplant recipients.

In the well designed, phase III trials BENEFIT and BENEFIT-EXT (in patients receiving kidneys from living/standard-criteria or extended-criteria donors, respectively), a belatacept-based treatment regimen was noninferior to a cyclosporine (ciclosporin)-based regimen with regard to patient and graft survival and acute graft rejection rate, and was significantly superior to the cyclo-sporine-based regimen with regard to the rate of renal impairment (in BENEFIT only), at 12 months.

Belatacept-based treatment showed long-term efficacy and remained effective after 2, 3, and 4 years with regard to these endpoints.

Belatacept was generally well tolerated in patients with kidney transplants from living, standard-criteria, or extended-criteria donors. The most serious adverse events that have been reported with belatacept treatment are post-transplant lymphoproliferative disorder, other malignancies, and serious infections.

At month 12, the incidence of new-onset diabetes mellitus after transplant was significantly lower with belatacept than with cyclosporine, and belatacept recipients had significantly lower blood pressure and a significantly smaller increase in certain lipid levels than cyclosporine recipients.


Cyclosporine Kidney Transplant Acute Rejection Mycophenolate Mofetil Abatacept 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Acknowledgments and Disclosures

The manuscript was reviewed by: A. B. Jain, Department of Surgery, Temple University Hospital, Philadelphia (PA), USA; M. Naesens, Department of Nephrology and Renal Transplantation, University Hospital Leuven, Leuven, Belgium; L. L. Rostaing, Department of Nephrology, Hemodialysis and Transplantation, CHU Toulouse, Toulouse, France.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.


  1. 1.
    Snanoudj R, Zuber J, Legendre C. Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs 2010; 70(16): 2121–31PubMedCrossRefGoogle Scholar
  2. 2.
    Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010; 73(5): 333–43PubMedGoogle Scholar
  3. 3.
    Bristol-Myers Squibb. Nulojix® (intravenous belatacept): US prescribing information [online]. Available from URL: [Accessed 2012 Jun 21]
  4. 4.
    European Medicines Agency. Nulojix® (intravenous belatacept): EU Summary of product characterisitics [online]. Available from URL: [Accessed 2012 Jun 21]
  5. 5.
    Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005 Mar; 5(3): 443–53PubMedCrossRefGoogle Scholar
  6. 6.
    Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with belatacept mediated CD28-CD80/86 blockade. Transplant Immunol 2007; 17(4): 243–8CrossRefGoogle Scholar
  7. 7.
    Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and inter-leukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008 Oct; 8(10): 2086–96PubMedCrossRefGoogle Scholar
  8. 8.
    Furuzawa-Carballeda J, Lima G, Uribe N, et al. High levels of IDO-expressing CD16+ peripheral cells, and tregs in graft biopsies from kidney transplant recipients under belatacept treatment [abstract no. 101]. Am J Transplant 2010; 10 Suppl. s2: 24–5Google Scholar
  9. 9.
    Grimbert P, Audard V, Diet C, et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrol Dial Transplant 2011; 26(3): 1087–93PubMedCrossRefGoogle Scholar
  10. 10.
    Ganguly BJ, Kulbokas EJ, Brickman D, et al. A comparison of the peripheral blood mrna transcriptional profiles of belatacept-and cyclosporine-treated renal transplant patients [abstract no. MO-041]. Transplant Int 2011; 24 Suppl. s2: 116Google Scholar
  11. 11.
    Bahri R, Naji A, Menier C, et al. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 2009 Dec 1; 183(11): 7054–62PubMedCrossRefGoogle Scholar
  12. 12.
    Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of be-latacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10(3): 535–46PubMedCrossRefGoogle Scholar
  13. 13.
    Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10(3): 547–57PubMedCrossRefGoogle Scholar
  14. 14.
    Shen J, Lee S, Townsend R, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of belatacept in kidney transplant recipients (KTR) after conversion from CNI-based regimens [abstract no. 939]. Am J Transplant 2012 May; 12 Suppl. s3: 301–2Google Scholar
  15. 15.
    Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. New Engl J Med 2005; 353(8): 770–81PubMedCrossRefGoogle Scholar
  16. 16.
    Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6(2): 430–9PubMedCrossRefGoogle Scholar
  17. 17.
    Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21(9): 1587–96PubMedCrossRefGoogle Scholar
  18. 18.
    Rostaing L, Neumayer HH, Reyes-Acevedo R, et al. Belatacept- versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol 2011 Nov; 6(11): 2696–704PubMedCrossRefGoogle Scholar
  19. 19.
    Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine a-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90(12): 1528–35PubMedCrossRefGoogle Scholar
  20. 20.
    Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012 Jan; 12(1): 210–7PubMedCrossRefGoogle Scholar
  21. 21.
    Medina Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12(3): 630–9CrossRefGoogle Scholar
  22. 22.
    Florman S, Bresnahan B, Chan L, et al. Three year outcomes in Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no. 1091]. Am J Transplant 2011 Apr; 11 Suppl. s2: 350Google Scholar
  23. 23.
    Florman S, Becker T, Bresnahan B, et al. Three-year outcomesbydonor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT & BENEFIT-EXT) [abstract no. 229]. Am J Transplant 2011; 11 Suppl. s2: 100Google Scholar
  24. 24.
    Durrbach A, Florman S, Zhang R, et al. Four-year outcomes by donor type from the long-term extension of the belatacept BENEFIT and BENEFIT-EXT studies [abstract no. 1293]. Am J Transplant 2012 May; 12 Suppl. s3: 407Google Scholar
  25. 25.
    Rostaing L, Reyes-Acevedo R, Neumayer H-H, et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase 3 belatacept studies [abstract no. O-243]. Transplant Int 2011; 24 Suppl. s2: 69Google Scholar
  26. 26.
    Dobbels F, Wong S, Joo S, et al. Health-related quality of life after kidney transplantation: results from belatacept clinical trials [abstract no. 1099]. Am J Transplant 2011; 11 Suppl. s2: 352Google Scholar
  27. 27.
    Larsen C, Alberu J, Massari P, et al. 4-year results from the long-term extension of the belatacept BENEFIT study [abstract no. 186]. Am J Transplant 2012 May; 12 Suppl. s3: 82Google Scholar
  28. 28.
    Florman S, Durrbach A, Grinyo J, et al. 4-year results from the long-term extension of the belatacept BENEFIT-EXT study [abstract no. 187]. Am J Transplant 2012 May; 12 Suppl. s3: 82Google Scholar
  29. 29.
    Larsen C, Grinyo J, Pestana JM, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [abstract no. 228]. Am J Transplant 2011; 11 Suppl. s2: 99–100Google Scholar
  30. 30.
    Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT Studies). Transplantation 2011; 91(9): 976–83PubMedCrossRefGoogle Scholar
  31. 31.
    Muelbacher F, Charpentier B, Larsen C, et al. Long-term safety of belatacept: 6 year results of a phase II study [abstract no. 621]. Transplantation 2008; 86 Suppl. 2S: 218CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations